Send2Press Newswire

USPTO Issues a Notice of Allowance for MMDI's BetaWire(TM) Guidewire Patent

Wed, 19 Nov 2008 10:51:10 GMT

MINNEAPOLIS, Minn., Nov. 19 (SEND2PRESS NEWSWIRE) -- Minnesota Medical Development, Inc. (MMDI) today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the company's BetaWire(TM) guidewire technology. The BetaWire(TM) is a super-torque interventional guidewire manufactured from a Beta Titanium alloy. Guidewires are thin, flexible wires that are used to facilitate the placement of balloon catheters and other diagnostic and therapeutic devices during coronary or peripheral interventional procedures.

"This is truly break through guidewire technology not seen before," said Steve Nuss, MMDI's Chief Marketing Officer. "Beta Titanium is an ideal alloy for interventional guidewires, its unique properties combine the best attributes found in conventional guidewire alloys such as Nitinol and stainless steel," he added.

Interventional Cardiologists that have evaluated the BetaWire for MMDI have been extremely impressed with its performance attributes such as precise one-to-one torque transmission, guidewire advancement, tip shaping and retention, flexibility and kink resistance.

MMDI has worked diligently to receive issuance of this U.S. patent. Millions of interventional guidewires are used every year throughout the world and MMDI believes that the BetaWire has the potential to make a significant impact on the market. Separately, MMDI also expects to receive international patent protection for the BetaWire in the very near future.

The Company will be seeking potential strategic partners for licensing, sales or distribution of their guidewire technology.

Additional information can be obtained by contacting Steve Nuss, Chief Marketing Officer at 763-354-7105 or snuss@2mdinc.com. You may also visit our website at: www.2mdinc.com.

About MMDI

MMDI was established in 2001 and is based in Plymouth, Minnesota. Located in the heart of Minnesota's "Medical Alley," MMDI has access to some of the world's finest medical product development, manufacturing and marketing resources. The Company's primary objective is to identify, develop, patent and manufacture unique medical devices that provide significant clinical benefits and market opportunities.

Copyright © 2008 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, Minnesota Medical Development, BetaWire medical guidewire

Shortness of Breath? Stronger Lungs for Better Breathing (100-percent Drug Free)

Tue, 18 Nov 2008 12:55:34 GMT

MIAMI, Fla., Nov. 18 (SEND2PRESS NEWSWIRE) -- The Expand-A-Lung(TM) Breathing Resistance Exerciser from Expand-A-Lung, Inc. was selected the #1 choice of the L.A. Times for breathing fitness training. Jorge Brouwer, inventor of the most compact (4-inches) breathing exerciser, manufactures and markets the easy to use "Expand-A-Lung."

When asked about how his product's success, Mr. Brouwer said, "We're finally creating awareness about the importance of breathing fitness training for athletes and people who suffer from shortness of breath due to respiratory problems such as COPD. This exercise directly works the muscles involved in the breathing process (the diaphragm and intercostals muscles), and allows you to breath in or inhale more volume of air/oxygen deeper into your lungs. It also helps you to get rid of more carbon dioxide out of your lungs when you exhale. The end result is an increase in lung capacity for better breathing and superior performance."

He added, "Research supports that the condition of the respiratory system is very important for endurance sports, and that respiratory fitness training can improve performance significantly in competitive athletes. It's a 100% drug free endurance booster through better breathing."

"In the past, this type of exercise was only available with bulky equipment in training facilities. The Expand-A-Lung's pocket size (4-inches) provides the portability to take it and use it anywhere. This is the design feature that made it popular among athletes who most frequently use it outdoors and at home."

The Expand-A-Lung(TM) is sold directly to the consumer through two separate web sites for $29.95 ea., including shipping. For further information call (305) 665-5787, or:

For athletes, visit www.expand-a-lung.com.

For COPD patients, visit www.copd-breather.com.

Copyright © 2008 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, Expand-A-Lung Inc, Breathing Resistance Exerciser

MMDI's Rebound HRD(R) Receives Separate Reimbursement Procedure Coding for Laparoscopic Inguinal Hernia Repair

Tue, 12 Aug 2008 13:18:45 GMT

MINNEAPOLIS, Minn. (SEND2PRESS NEWSWIRE) -- Minnesota Medical Development, Inc. (MMDI) today announced that the Centers for Medicare & Medicaid Services (CMS) have agreed to create seven new ICD-9-CM reimbursement procedure codes for its new Rebound HRD (Hernia Repair Device). The new coding will become effective October 1, 2008. The Rebound HRD was recently FDA 510(k) cleared and is intended to assist in the repair and/or reinforcement of hernia or other soft tissue defects where weakness exists and where the support of a nonabsorbable material is preferred.

The new coding options will delineate from the existing codes to identify the Rebound HRD as an inguinal hernia repair device which can be used specifically for laparoscopic hernia repair. Previously, CMS coding did not recognize the surgical differences between "open incisional" and "laparoscopic" types of hernia repair.

The Rebound HRD is a self-expanding Nitinol framed/surgical mesh medical device designed for the laparoscopic repair of both inguinal and ventral hernias. The super-elastic Nitinol frame allows the device to be folded and inserted laparoscopically. Once deployed, the device fully unfurls or "rebounds" back to its original shape - ready for quick and easy placement over the hernia defect. The Rebound HRD conforms to the anatomy while providing stability; eliminating the need for anchoring, which in turn, minimizes patient post-op discomfort and the risk of nerve/blood vessel injury. Although the Rebound HRD is ideally suited for laparoscopic surgery it may also be placed via an open incisional approach.

Mary Corkins, co-founder of The Reimbursement Group in Chicago, counseled MMDI with regard to the reimbursement and coding of the Rebound HRD. "In the early stages of our conversations with Mary, it became evident that the unique laparoscopic usability of the Rebound HRD was also an opportunity to influence the creation of separate codes for laparoscopic inguinal hernia repair," said MMDI Chief Marketing Officer, Steve Nuss. "We are very pleased that we have seized this opportunity. Establishment of these new codes acknowledges the groundbreaking technology and engineering behind the Rebound HRD," he added.

In 2006, The Society of Laparoendoscopic Surgeons (SLS) recognized the Rebound HRD as one of the "2006 Innovations of the Year." The SLS acknowledged the Rebound HRD as part of its 15th International Congress and Endo Expo 2006, held September 6-9 in Boston, Massachusetts.

Additional information can be obtained by contacting Steve Nuss, Chief Marketing Officer at 763-354-7105 or snuss@2mdinc.com. You may also visit our website at: www.2mdinc.com.

The SLS does not endorse or approve any products.

About MMDI
MMDI was established in 2001 and is based in Plymouth, Minnesota. Located in the heart of Minnesota's "Medical Alley," MMDI has access to some of the world's finest medical product development, manufacturing and marketing resources. The Company's primary objective is to identify, develop, patent and manufacture unique medical devices that provide significant clinical benefits and market opportunities.

All trademarks acknowledged.

Copyright © 2008 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, Minnesota Medical Development, Rebound Hernia Repair Device

Expand-A-Lung(TM) Breathing Resistance Exerciser Selected as Top Choice for Respiratory Fitness Training by the L.A. Times

Mon, 16 Jun 2008 23:45:30 GMT

MIAMI, Fla., June 16 (SEND2PRESS NEWSWIRE) -- Have you exercised your lungs today? The Expand-A-Lung(TM) Breathing Resistance Exerciser has been selected as the top choice for respiratory fitness training by the L.A. Times. Jorge Brouwer, inventor of the most compact (4-inches) breathing exerciser, manufactures and markets the easy to use "Expand-A-Lung." When asked about how his product's success, Mr. Brouwer said, "We're finally creating awareness about the importance of respiratory fitness training for athletes and people who suffer from shortness of breath due to respiratory problems such as COPD."

He added, "This exercise works the muscles involved in the breathing process (the diaphragm and intercostals muscles), and allows you to breath in more volume of air/oxygen deeper into your lungs. It also helps you to expulse more carbon dioxide out of your lungs. The end result is deeper, easier and better breathing inhaling and exhaling (100% drug free)."

Research supports that the condition of the respiratory system is very important for endurance sports, and that respiratory fitness training can improve performance significantly in competitive athletes. Furthermore, it can also be extremely efficient as an integral part of a pulmonary rehabilitation program for COPD patients."

"In the past, this type of exercise was only available with bulky equipment in respiratory care facilities. The Expand-A-Lung's size (4-inches) provides the portability to take it and use it anywhere. This is the feature that made it popular among athletes who most frequently use it outdoors."

The Expand-A-Lung(TM) is sold directly to the consumer through two separate web sites for $29.95 ea.

For further information call (305) 665-5787 or go online:
- For athletes, visit www.expand-a-lung.com.
- For COPD patients, visit www.copd-breather.com.

All trademarks acknowledged.

Copyright © 2008 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, respiratory fitness training, COPD patients and treatment

New Treatments for Kidney Cancer Offer Hope, but Create Difficult Choices for Cancer Patients

Fri, 07 Sep 2007 17:00:00 GMT

Oncologist Dr. David Minor to discuss new options for patients and their families for disease that knows no known cure

SAN FRANCISCO, Calif. - Sept. 7 (SEND2PRESS NEWSWIRE) -- California Kidney Cancer Foundation Executive Director, Dr. David Minor will present a review of treatments for metastatic kidney cancer as presented at the most recent American Society of Clinical Oncology Conference. The presentation will be from 3 to 5 PM on September 15, 2007 at California Pacific Medical Center, 2333 Buchanan Street, San Francisco, Calif.

Kidney cancer is one of the most fatal forms of cancers and is increasing in frequency. According to the American Cancer Society, more than 35,000 Americans will be diagnosed with kidney cancer in 2007. More than 13,000 people will succumb to the disease. Kidney cancer is the 7th most common cancer among men in America. There is no known cure for metastatic kidney cancer, which usually impacts, lungs, brain and bones.

"The progress made by researchers and pharmaceutical companies on treatments for kidney cancer over the past 24 months has been nothing short of spectacular," said Dr. David Minor. He added, "But with all the new options, there are many new choices for treatment and since many of the new drugs are giving in combination, planning the correct course of treatment has become more complex. By educating doctors, urologists, patients and their family members, we have a real shot at saving and prolonging lives."

Those wishing to attend the presentation should contact Dana Monroe at the California Kidney Cancer Foundation at danamariemonroe@comcast(.net) or 415-885-8600. Driving and parking directions can be found at www.ckcc.org.

About the California Kidney Cancer Foundation
The Foundation's activities are directed at ongoing exploration of cures, treatments and patient support for kidney cancer patients. The Foundation believes that many of the lessons learned from kidney cancer treatment may be relevant to the treatment of other forms of cancer. The Center research activities are funded by the California Kidney Cancer Foundation, a nonprofit foundation.

More information can be found at www.ckcc.org/foundation.htm.

Media Contact:
Steve Kazan
California Kidney Cancer Foundation
+1-650-315-8696
curekidneycancer @ gmail.com

CA Kidney Cancer Foundation
2100 Webster St. Suite. 326, San Francisco, CA 94115
Phone +1-415-885-8600 - Fax +1-415-885-8680

Copyright © 2007 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, California Kidney Cancer Foundation, treatments for metastatic kidney cancer

MMDI's Rebound HRD(TM) Receives FDA 510(k) Clearance

Tue, 21 Aug 2007 15:46:00 GMT

MINNEAPOLIS, Minn. - Aug. 21 (SEND2PRESS NEWSWIRE) -- Minnesota Medical Development, Inc. (MMDI) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its new Rebound HRD(TM) (Hernia Repair Device). The Rebound HRD is intended to assist in the repair and/or reinforcement of hernia or other soft tissue defects where weakness exists and where the support of a nonabsorbable material is preferred. MMDI also recently received ISO 13485:2003 (Quality Management) and Directive 93/42/EEC (CE Mark) certifications for the design, manufacture and distribution of its Rebound HRD(TM) in European Union member countries.

The Rebound HRD(TM) is a self-expanding Nitinol framed/surgical mesh medical device designed for the laparoscopic repair of both inguinal and ventral hernias. The super-elastic Nitinol frame allows the device to be folded and inserted laparoscopically. Once deployed, the device fully unfurls or "rebounds" back to its original shape - ready for quick and easy placement over the hernia defect. The Rebound HRD(TM) conforms to the anatomy while providing stability; eliminating the need for anchoring, which in turn, minimizes patient post-op discomfort and the risk of nerve/blood vessel injury. Although the Rebound HRD(TM) is ideally suited for laparoscopic surgery it may also be placed via an open incisional approach.

"The FDA's 510(k) clearance of the Rebound HRD(TM) serves as recognition for the efforts of many who contributed to the planning, product development and testing of the device and its manufacture. Its basic design lends itself to being manufactured in many shapes, sizes and configurations -- the possibilities are limitless and we are already in the process of developing additional models to accommodate a wider variety of soft tissue repairs," said MMDI Chief Marketing Officer, Steve Nuss.

"In the United States alone, over 800,000 inguinal and ventral hernias are repaired annually using surgical meshes. Industry experts are predicting steady growth in that number as the baby boomer generation continues to age and the incidence of obesity increases," he added.

In 2006, The Society of Laparoendoscopic Surgeons (SLS) recognized the Rebound HRD(TM) as one of the "2006 Innovations of the Year." The SLS acknowledged the Rebound HRD(TM) as part of its 15th International Congress and Endo Expo 2006, held September 6-9 in Boston, Massachusetts.

Additional information can be obtained by contacting Steve Nuss, Chief Marketing Officer at 763-354-7105 or snuss@2mdinc(.com). You may also visit our website at: www.2mdinc.com.

The SLS does not endorse or approve any products.

About MMDI
MMDI was established in 2001 and is based in Plymouth, Minnesota. Located in the heart of Minnesota's "Medical Alley," MMDI has access to some of the world's finest medical product development, manufacturing and marketing resources. The Company's primary objective is to identify, develop, patent and manufacture unique medical devices that provide significant clinical benefits and market opportunities.

Copyright © 2007 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, Rebound HRD Hernia Repair Device, Minnesota Medical Development Inc

HearPod, Inc. Provides Baby Boomers with Quality Hearing Aid Options

Fri, 15 Jun 2007 14:24:00 GMT

CORNELIUS, N.C. - June 15 (SEND2PRESS NEWSWIRE) -- Communication is the foundation for an incredible life at work, with friends, and especially at home. That's why so many baby boomers are turning to HearPod 32X to power up their hearing. Baby boomers have a reputation for expecting the best and many will not settle for less. However, cost can sometimes interfere when purchasing a quality hearing aid.

"Our 32-channel, 100 percent, digital HearPods are as good, if not better than, the most expensive hearing aids available," Randy Wohlers, President of HearPod, Inc. said. "And, we can offer a savings of two thirds the average cost."

Many quality hearing aids range in price from $4,000 to $8,000 per pair, but Hearpod's 32X digital HearPods start at $595; the most expensive, directional open fitting is $995.

According to Wohlers there is no other technologically advanced, quality product being offered on the market at such a competitive price.

"We use the highest level of digital technology available. It's priced right and accompanied by great service," Wohlers explained. "Baby boomers want the best, in a timely manner, and at a fair price; we have done that for them. The word is out that our digital technology is tops for hearing loss."

Wohlers is a baby boomer and personally understands this target market. He knows that this group would not consider getting a hearing aid that was inferior simply because it cost less.

While many baby boomers can afford the higher prices, replacing them every few years can become a financial challenge; people may sacrifice hearing for money and may not seriously pursue buying a quality hearing aid.

HearPod has changed the playing field and baby boomers are discovering that hearing does not have to be sacrificed because of money.

"This is the third set of hearing aids I've had and they've easily been the best," one happy New York customer said. "I started out with custom fitted and programmed units through a local dispenser for $3,000. They didn't last and I decided to try some cheaper ones found on the Internet; they fell apart. The quality of HearPod's hearing aids is better than the ones I purchased for $3,000. They were custom programmed and every bit as comfortable."

HearPod's customer service is also a cut above the rest. It makes patients stand up and say "great job" because they receive this service in the comfort of their home.

HearPod provides quick and efficient customer service through a 24/7 Customer Care Line: 800 851-5128, and e-mail service. They often surprise their customers by how quickly they respond to questions and needs.

"HearPods are not for everyone," Wohlers said. "The ideal customer is computer savvy and able to understand easy, online directions. We provide online videos and owners' manuals to teach our customers how to clean and care for their HearPods. We encourage independence and want to see our customers happy."

Another customer from Tennessee explains that HearPods have made a tremendous difference in his work and personal life. Not only did he feel that the product was superior, but that the service went beyond the call of duty.

"HearPod's due diligence to ensure that I had the proper accessories to make the product work was impressive," he said. "Their service is second to none."

So, how simple is it to purchase a HearPod? Customers first send in their physician's hearing-test results and a prescription is fit. It is then delivered to the customer's home within less than a week and comes with a 45-day money-back guarantee.

For additional information, call: Randy Wohlers at: 1-808-216-2747; e-mail: customerservice@myhearpod.com; or visit the web site at: www.MyHearPod.com.

Copyright © 2007 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, baby boomers hearing loss, HearPod hearing aids

Crescent Diagnostics Announces Positive Clinical Results for its Novel Bone Quality Test, BQT(TM)

Fri, 08 Jun 2007 15:52:00 GMT

Study results provide further evidence of the potential of BQT(TM) as a test for osteoporosis

LONDON, UK - June 8 (SEND2PRESS NEWSWIRE) -- Crescent Diagnostics Ltd ("Crescent"), today announced the publication of a recent study demonstrating the potential of the Bone Quality Test, BQT(TM) to diagnose osteoporosis. More women at risk can be screened with an accurate, simple to use test which does not require a hospital visit.

Crescent is conducting multiple clinical studies to investigate the ability of the BQT(TM) to detect osteoporosis and expand the screening of women at risk. The most recent published study carried out at the University of Limerick, Ireland compared the potential of the BQT(TM) to identify patients at risk of fracture with DXA, the current reference standard that measures bone mineral density ("BMD"). The study compared the fingernail clippings of 169 patients, 39 with a history of fracture and the remainder in a control group with no fracture history.

The lower disulphide content in nails obtained from patients with a history of fracture was statistically significantly lower than in patients without a history of fracture (p=0.025). 26 out of 39 subjects (67%) with a history of fracture recorded values below the cut-off value for disulphide content of the nail as measured by Raman spectroscopy.

Commenting on these findings Ernest Poku, Chief Executive Officer of Crescent said, "We are pleased that these preliminary results confirm the earlier clinical findings and show the potential of the BQT to aid the identification of individuals at risk of osteoporosis at a much lower cost than current tests."

Crescent recently began recruiting patients for FRAN, a large multi-centre trial in the UK and Ireland. This study aims to demonstrate the potential of the BQT(TM) to evaluate fracture risk in hundreds of post-menopausal women. The results are expected in early 2008.

Mr. Poku explained that Crescent "now plans to enter into dialogue with regulatory agencies to determine the optimum route to market approval for the test." The company is planning to complete a Series A funding round in early 2008 to provide the funding to complete the BQT(TM) regulatory process.

Crescent, founded in 2004, is a development stage diagnostic company focused on advancing its BQT(TM). Low cost accurate alternatives to DEXA are needed to enable wider osteoporosis screening.

About Crescent Diagnostics Ltd
Crescent Diagnostics is redefining the diagnosis and treatment of osteoporosis by developing the BQT(TM), a novel test which assesses human fingernail structure as a surrogate marker for bone structure. A BQT(TM) Point of Care test could be simple and accurate enough to enable wider population screening, addressing a market exceeding $700m. Crescent Diagnostics has offices in Limerick, Ireland and London, UK. For more information visit www.crescentds.com.

About Bone Quality Test, BQT
The Bone Quality Test is a Raman spectroscopy analysis performed on the nail in-situ or on a nail clipping. The results are highly repeatable and the test can be delivered at the point of care cost effectively. The BQT(TM) addresses the need for more accurate osteoporosis testing to reduce fractures in the community which costs billions of dollars worldwide annually.

Journal Reference:
Towler et al - Journal of Materials Science: Materials in Medicine. J Mater Sci: Mater Med (2007) 18:759-763. Published as epub ahead of print 30 November 2006

Copyright © 2007 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, Bone Quality Test, Crescent Diagnostics Ltd

Osmetech Licenses Roche Hot Start(R) Polymerase Technology

Tue, 05 Jun 2007 22:54:00 GMT

PASADENA, Calif. - June 5 (SEND2PRESS NEWSWIRE) -- Osmetech plc (AIM; LSE) today announced that it has been granted a non-exclusive worldwide diagnostics license from Swiss-based F. Hoffman LaRoche Ltd and its US affiliate Roche Molecular Systems Inc. (collectively "Roche") to use Hot Start(R) polymerase technology in Osmetech nucleic acid diagnostic assays.

This license allows Osmetech to include Hot Start(R) polymerase as part of the diagnostic kit providing Osmetech customers with a cost savings and level of convenience, and demonstrates Osmetech's diagnostic commitment of including everything in a kit rather than having the customer source and license components from various vendors.

This latest license complements our highly sensitive electrochemical detection platform that is backed by an extensive patent portfolio, says Osmetech CEO James White. "We have over 145 granted patents worldwide,and several key in-licenses, built on acquisitions and collaborations with the likes of Harvard University, California Institute of Technology (Caltech), Motorola, Clinical Micro Sensors, Inc., University of North Carolina, Concordia University, Johns Hopkins University, University of Michigan, University of Washington, and Epidauros. This agreement with Roche will provide an added benefit for our customers who will not be required to obtain this license from Roche and pay Hot Start(R) polymerase royalties on tests performed when using Osmetech products."

In 2006 Osmetech launched the eSensor(R) platform, an FDA cleared electrochemistry-based array system for cystic fibrosis carrier detection, and is currently in the process of completing its next generation instrument, the eSensor(R) XT8. Osmetech plans to seek FDA approval for and launch of this instrument with a CYP450/VKOR, a test to determine a patient's response to warfarin, later this year. The CYP450/VKOR assay is the first of many pharmacogenomic assays planned for the system, which is designed to meet the needs of the rapidly expanding field of personalized medicine.

About Osmetech
Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international molecular diagnostics business with operations in Boston and Pasadena in the US, serving the high growth, near patient testing market targeting small to medium sized hospitals. Osmetech has launched eSensor(R), an FDA cleared electrochemistry-based array system, for cystic fibrosis carrier detection and plan to launch a number of pharmacogenomic assays utilizing the same proprietary technology.

More information: www.osmetech.com.

Ticker: AIM LSE: OMH (London Stock Exchange)

Alma Lasers(TM) Receives FDA Clearance for the Accent(TM) Dual Mode RF System

Mon, 30 Apr 2007 15:44:00 GMT

BUFFALO GROVE, Ill. - Apr. 30 (SEND2PRESS NEWSWIRE) -- Alma Lasers a global leader in laser, light-based, and radio frequency (RF) technologies used in aesthetic medicine announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Accent(TM) Dual Mode RF System in the United States.

Receiving its first FDA indication for the treatment of wrinkles and rhytids, the Accent System has been used successfully by medical professionals worldwide to treat a variety of dermatological and aesthetic conditions.

"We're delighted to receive the marketing clearance for the Accent product in the U.S.," stated Howard Kelly, CEO for Alma Lasers. "The unique dual mode RF modalities of the Accent system will provide physicians with the most advanced technology available in non-invasive aesthetic medicine, creating a higher standard in patient satisfaction. The Company is committed to pursuing additional clearances from the FDA, in order to expand the clinical indications for the Accent system in the United States."

Non-invasive, non-ablative, and virtually pain free, the Accent system combines two radio frequency modes into one device. Each mode is delivered by a discrete handpiece to enable volumetric RF thermotherapy at different tissue depths within the body.

In the BiPolar mode, RF energy penetrates the skin superficially, facilitating the treatment of areas where skin is thinner and more delicate such as areas of the face where the skin rests directly over the bone. The Alma proprietary UniPolar? mode, delivers RF energy deep into the dermal and sub-dermal layers to efficiently treat large volumes of tissue. Unlike other RF based technologies, the Accent system does not require consumables. Therefore, treatments are clean, efficient and economical.

Ziv Karni PhD President and founder of Alma Lasers stated; "The Accent product was engineered for safety and ease of use while maximizing efficacy. The continuous movement of either handpiece results in a gradual build-up of heat to achieve the optimal therapeutic effect, while offering greater patient comfort. With over one thousand Accent systems installed world wide, the product has enjoyed an unparalleled safety record."

"Non-invasive treatments are the largest and fastest growing category in aesthetic medicine," said Yariv Matzliach, Executive Vice President of Global Marketing for Alma Lasers. "The Accent system has been approved for use in Europe, Asia, Australia, Latin America and Canada, where dermatologists, plastic surgeons, OB/GYN's and general practitioners have achieved outstanding results and a consistently high level of patient satisfaction. Now with its first FDA cleared indications, the Accent system is poised to provide medical professionals and their patients in the United States with a new level of safety, efficacy and satisfaction in the non-invasive treatment of wrinkles and rhytids using a combined treatment with Unipolar and Bipolar RF technologies."

According to one Principal Investigator in the FDA study, Macrene Alexiades-Armenakas, MD, PHD, Assistant Clinical Professor, Yale University School of Medicine, and Director, Dermatology and Laser Surgery in New York City, "I found the Accent system to be superior to prior generations of RF technology in the treatment of skin laxity, particularly on the neck. It is also a remarkable breakthrough that the system is painless and requires no anesthesia. Accent treatments can be performed rapidly with no downtime and can be applied concurrently with other non-ablative modalities, such as injectables to achieve better results in what is termed the 'non-surgical facelift.' Immediate skin tightening is evident and the results are often considered striking."

"We have found the Accent system to be very safe and relatively comfortable with a high percentage of responders," states David H. McDaniel, MD, Assistant Professor of Clinical Dermatology and Plastic Surgery, Eastern Virginia Medical School, and Director of the Institute of Anti-Aging Research Center of Virginia in Virginia Beach. "Compared to other RF devices we have used, treatment with the Accent system is much less painful, faster and easier to perform. It also allows more 'artistic' use on the face. Although responses vary, a high percentage of treated subjects showed a visible response. Some observe an immediate skin tightening of the face. Many of the subjects noticed a difference in the way their clothes fit after a few treatment sessions. It can also be used as part of a broader spectrum of non-surgical facial rejuvenation treatments or procedures which might include fractional resurfacing, IPL or LED photomodulation, and Botox? or other injectable fillers."

Maurice Sherman, MD, Associate Professor of Clinical Surgery, University of California - San Diego, and the owner of the Del Mar Cosmetic Medical Center in southern California, said "We obtained remarkably good results with the Accent system. It was consistent for all of the patients that followed the protocol. All of them showed an improvement. Some dramatic, some moderate, but every patient expressed satisfaction with the results. Everyone said that their skin felt tighter the day after the first treatment." Added Dr. Sherman, "Of all the RF systems on the market today, I feel the Accent is the most effective technology out there."

About Alma Lasers
With over 1000 Accent installations worldwide, Alma Lasers is a global developer, manufacturer and marketer of laser, light-based, and radio frequency devices for aesthetic applications. Since 1980, the founders of Alma Lasers have been at the forefront of innovative technologies for use in aesthetic medicine. Technical expertise combined with a thorough understanding of practitioners' needs led to the development of Alma Lasers' multi-technology / multi-application systems.

The Company's mission is to provide modular, cost-effective and high performance systems that enable medical practitioners to confidently offer safe, effective, and profitable aesthetic treatments.

More information about Alma Lasers can be found at www.almalasers.com.

Alma Lasers Reaches Favorable License Agreement with Palomar Medical Technologies

Tue, 03 Apr 2007 17:15:00 GMT

Parties settle on-going patent litigation

BUFFALO GROVE, Ill. - Apr. 3 (SEND2PRESS NEWSWIRE) -- Alma Lasers announced earlier today that it has resolved an ongoing patent litigation with Palomar Medical Technologies that involves certain U.S. hair removal patents. Palomar has an exclusive license for these patents, owned by the General Hospital Corporation in Boston, Massachusetts.

Under the terms of the license agreement, Alma Lasers has been granted a nonexclusive license by Palomar and MGH. These terms are comparable to those agreed to by other licensees of these patents, including medical aesthetic device companies Cynosure and Cutera. After a nine month period at a slightly higher rate, Alma Lasers will pay a 7.5% on-going royalty rate to Palomar on dedicated hair removal products.

In addition, Alma Lasers agreed to certain trade dress concessions involving the Harmony and Aria product lines that will be implemented over the next six months. These changes will affect the look but not the function or underlying technologies associated with the Harmony and the Aria platform. Alma Lasers is confident that these trade dress modifications will have minimal impact to the company business strategy. The company will have the freedom to continue to supply upgrades, introduce new modules, replacement handpieces and other products to the current Harmony and Aria customer base. There will also be no impact or interruption to current or future product development.

Howard Kelly, Chief Executive Officer of Alma Lasers, stated "This resolution is a positive one for both our customers and investors. It avoids the cost and uncertainty of a lengthy litigation and removes a significant distraction from the business. Alma Lasers can now focus on the key tasks at hand, which is to grow a profitable business based on superior platform technology, innovation, and outstanding customer service."

A leader in the industry, Alma Lasers has pioneered revolutionary new technologies for the medical aesthetic market over the past seven years. In the spirit of moving the industry forward with free market innovation and a focus on customer needs, Alma Lasers had hoped to avoid this litigation. Moving forward, Alma Lasers will continue to focus on innovation through technology that best serves our customers, physicians and their patients.

About Alma Lasers, Ltd.
Alma Lasers, Ltd. is a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for aesthetic and medical applications. Since 1980, the founders of Alma Lasers have been at the forefront of innovative laser and light-based medical technology. Their technical expertise and in-depth understanding of practitioners' needs led to the development of Alma Lasers' multi-technology/multi-application systems. Alma Lasers' mission is to provide modular, cost-effective and high performance designs that enable medical practitioners to confidently offer safe, effective and profitable aesthetic treatments to their patients.

More information about Alma Lasers can be found at www.almalasers.com.

Alma Lasers = Wellbeing Through Technology

Text provided by the news source.

HearPod Hearing Aids Offer Low Cost High Tech Solutions

Mon, 02 Apr 2007 20:00:00 GMT

CORNELIUS, N.C. - Apr. 2 (SEND2PRESS NEWSWIRE) -- According to HearPod Hearing Aids millions of Americans who suffer from hearing loss and could benefit from hearing aids don't wear them. High cost is often cited as the reason. A National Council on the Aging survey showed that 55 percent of surveyed seniors not using hearing aids find cost to be a barrier.

Until recently, seniors had little choice. Either pay the high cost of hearing aids at a hearing aid store, or go without. It's a problem that drove hearing aid expert Randy Wohlers, BC-HIS to offer seniors an innovative solution-high-quality, custom-programmed hearing aids at a huge savings via the website www.myhearpod.com.

Wohlers, who is a board certified hearing instrument specialist and the owner of a chain of hearing aid stores, knows well how hearing aid prices have soared in recent years. He says that as the technology of hearing aids has become more sophisticated, hearing aid manufactures have understandably charged more for their products, forcing retailers to do the same. Two years ago he decided there was a better way. "It had just gotten to the point that many people were simply priced out of the market," says Wohlers. "I knew there was a better way to get people high-quality hearing aids at a price they could afford."

In 2005, Wohlers launched his HearPod line of hearing aids that offers the same features of leading manufacturers, including the latest noise-reduction, voice-enhancement and 100% digital technology. Customers can choose from both behind the ear or in the canal models that come with custom ear molds as an option.

HearPod customers are first encouraged to see their doctor to ensure they can benefit from hearing aids, to get a hearing test and get the printed results of the test called an audiogram. A customer can then fax or email his audiogram to HearPod so the company can custom program the aid to match the customer's unique hearing loss, thereby providing maximum hearing benefit.

The completed aids are sent directly to the customer. HearPod offers round the clock customer service via its toll free customer care line. It also answers frequently asked questions about hearing aid use in its online tutorials. All aids come with a one-year warranty and a 45-day money back guarantee. With each purchase, customers receive a one years' supply of wax guards and batteries. Shipping is free.

Prices for HearPod aids are less than half the cost of comparable hearing aids purchased in a hearing aid store. For example, HearPod's most technologically sophisticated line of hearing aids, which offers 32 channel technology, open fitting and directional microphones costs under a thousand dollars. People can easily pay more than $2,500 for a comparable hearing aid at a retail store.

Wohlers attributes his low prices to the company's efficient manufacturing facility in North Carolina and to online distribution, which eliminates the costs that a traditional brick-and-mortar store would have.

To date, HearPod's customers have ranged from baby boomers looking for their first hearing aid to seniors wanting to replace older technology hearing aids or get more powerful aids to address their progressing hearing loss. "People want the highest quality and latest technology at a big savings and that's what we provide," says Wohlers.

The combination has proven successful as HearPod and its website www.myhearpod.com has risen to the top tier of online rankings. Wohlers says that there are other companies offering hearing aids via the Internet, but none offer HearPod's winning combination-100% digital technology, comfortable fit, full featured noise reduction technology, speech enhancement technology, optional custom ear molds, free wax guards, batteries and shipping, 24 hour customer service.

For more information on HearPod hearing aids, go to www.myhearpod.com or call the company's toll free customer care line 1-800-851-2414.

Text provided by the news source.

Alma Lasers Launches Soprano XL - A New Era in Laser Hair Removal

Fri, 09 Mar 2007 20:30:00 GMT

CAESAREA, Israel - Mar. 9 (SEND2PRESS NEWSWIRE) -- Alma Lasers Ltd. announced today the launch of a new era in laser hair removal with the launch of the Soprano XL system. Answering a long felt market need for comfortable hair removal, the Soprano XL uses unique technology to provide a viable solution. This virtually painless hair removal system is made possible by the combination of low fluence, rapid pulsing diode technology with an in-motion treatment technique.

The rapid pulsing capabilities of the system are enabled by the system's high average peak power, unique in the industry. This rapid pulsing makes possible a key aspect of virtually painless hair removal - "hair removal in motion".

The Soprano XL includes both the SHR (Super Hair Removal) mode for "in-motion" hair removal and the HR mode, which is a conventional diode laser mode.

Explaining the science behind the new hair removal paradigm, Ziv Karni, PhD, President of Alma Lasers said, "The SHR mode utilizes a series of low fluence, high repetition pulses to increase the temperature of both the hair follicle and the surrounding, nourishing tissue to 45 degrees C. This more gradual, in-motion heat delivery uses the chromophores in the surrounding tissue as reservoirs to effectively heat up the hair follicle.

This, along with the heat energy absorbed directly by the hair follicle, damages the follicle and prevents re-growth." The SHR mode protects the epidermis and provides a virtually painless treatment. The SHR mode is suitable for all skin types, hair types and most hair colors.

The advanced technology of Soprano XL is patent pending and Alma Lasers CEO Howard Kelly, states, "We are confident that the market will respond as enthusiastically to this product as our clinical sites have. We have developed a new paradigm for laser hair removal and since it is an in-motion technique, we feel that it is the perfect complement for Alma Lasers, the "in-motion" company.

According to David J. Friedman, MD, of Jerusalem, Israel and New York, one of the principle investigators for this new product, "The SHR mode of the Soprano XL, which is the in-motion mode, is remarkable, my patients love it. I don't find any of the resistance to treatment due to patient

discomfort that I have in the past. In addition, I have found the SHR mode to afford the darker skin patients an increased safety margin without a compromise in efficacy."

The Soprano XL launch was timed to coincide with the American Academy of Dermatology annual meeting taking place in Washington, DC from February 3rd to the 5th. Alma Lasers is certain that this new product will generate significant interest among dermatologists since it provides an elegant and effective solution to the on-going problem of laser hair removal - extreme patient discomfort.

About Alma Lasers, Ltd.
Alma Lasers, Ltd. is a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for aesthetic and medical applications. Since 1980, the founders of Alma Lasers have been at the forefront of innovative laser and light-based medical technology. Their technical expertise and in-depth understanding of practitioners' needs led to the development of Alma Lasers' multi-technology / multi-application systems.

Alma Lasers' mission is to provide modular, cost-effective and high performance designs that enable medical practitioners to confidently offer safe, effective and profitable aesthetic treatments to their patients.

More information about Alma Lasers can be found at www.almalasers.com.

Text provided by the news source.

MyHearPod Introduces Amazing New Line of 32-Channel Hearing Aids

Thu, 01 Mar 2007 12:00:00 GMT

CORNELIUS, N.C. - Mar. 1 (SEND2PRESS NEWSWIRE) -- HearPod Hearing Aids (www.MyHearPod.com) president Randy Wohlers, BC-HIS, announced today the introduction of a new line of 32-channel hearing aids. Each of the new products matches the company's current line of aids manufactured with four channels.

The key benefit of the 32-channel products is that they automatically adjust to optimize hearing in every environment.

*(Photo Caption: HearPod Directional Mic Open Fitting hearing aid.)

Wohlers says, "Our current four channel products can be adjusted for changing hearing environments-conversation, meetings, music, telephone-by simply touching the button on the aid. The 32-channel line does this automatically and has more sophisticated technology. It offers higher quality for more benefit."

The four new aids follow the nomenclature of the current line:

Those knowledgeable about hearing aid technology may be familiar with the Voyageur(TM) platform that is the core of HearPod's new 32-channel line. The aids are manufactured with ADRO(TM) technology from Dynamic Hearing. ADRO(TM) is a high-end alternative to standard sound compression configurations used in most hearing aids. It ensures that sounds remain within the dynamic range of the listener by employing fuzzy logic and an automatic algorithm to optimize the hearing aid signal.

ADRO(TM) separates the audio signal into 32 independent channels (64 bands), providing customers with extremely clear and natural sound. It uses fuzzy logic rules to optimize the required sound at the output of the hearing aid without compromising the signal.

The HearPod Directional Mic Open Fitting 32XD comes with automatic directional microphones which continuously and automatically adjustment the microphone settings based on the environment.

Additional features for this and all other 32-channel models are:

All HearPods are one hundred percent digital, providing state-of-the-art technology for the highest quality sound and the longest life.

Since it's founding in 2005, HearPod continues to revolutionize the hearing aid industry by offering high-quality low-cost hearing aids through its website myhearpod.com.

Wohlers explains that HearPod offers hearing aid shoppers a choice. He says, "It's no longer the case that people are locked into paying thousands of dollars for a hearing aid at a retail store, or having to settle for a low quality aid over the Internet. HearPod offers the high quality people want, but at the low price they can afford."

Wohlers adds that the company offers a level of customer service and quality that rivals most brick and mortar locations. HearPod offers a 24-hour customer care toll free number and an experienced team of hearing care experts to answer customer questions and make product recommendations.

HearPod customers receive a custom programmed hearing aid as they would from a retail store. HearPod customers are encouraged to see their physician before purchasing to ensure they need a hearing aid and to get an audiogram, which shows their individual degree of hearing loss. The audiogram values can be entered on the web order page, faxed toll free or emailed to HearPod so that the hearing aid can be programmed to correct for the individual's unique hearing loss.

The company provides a 45-day one hundred percent money-back guarantee and a one year warranty that covers the cost of any repairs and includes a year's worth of free batteries and wax guards for in-the-canal products. Extended warranties are also available. All HearPods are manufactured in the HearPod lab at 18636 Starcreek Drive, Suite E, Cornelius, North Carolina 28031 USA.

For more information on HearPod hearing aids, go to www.myhearpod.com or call the company's toll free customer care line 1-800-851-2414.

Text provided by the news source.

Enviromax Introduces a Stimulating Breakthrough in Prostate Massage and Traditional Therapy Alternative

Tue, 19 Dec 2006 16:38:00 GMT

ANCHORAGE, Alaska - Dec. 19 (SEND2PRESS NEWSWIRE) -- The Prostate Cradle External Massager, developed by Enviromax, based in Eagle River, Alaska, has been selling on the Internet since last March and the company is struggling to keep up with orders.

"I developed the Prostate Cradle out of necessity to help successfully deal with my enlarged prostate," Adam McVay, of Enviromax, said. "The response has been overwhelmingly positive."

McVay explains that he was faced with a choice of taking expensive prescription drugs, or having a biopsy leading to surgery, and more prescription drugs. He searched for an alternative and read about nutritional healing. During the process, he quit two of his three jobs, as well as sugar and caffeine. He felt better almost immediately and symptoms and aches in his prostate reduced within weeks.

As part of this new lifestyle, McVay sought out a non-invasive prostate massager, but could not find one; he began to research, develop and design a practical and useful model of his own.

"It took years to find the right shape, size and materials," McVay said, "but, once the Cradle took form, it helped massage my prostate back to health. It also improved the health of my sex life, which was an added bonus."

Enlarged prostates benefit from massage. The stimulation of blood flow and an increase in oxygen to the gland helps rinse the prostate of harmful bacteria and particles which build up over time, and can lead to tumors. A 10-20 minute prostate massage at least once a month, and as often as once a day, is important for a healthy gland.

The Prostate Cradle works using pressure from body weight which can be focused and controlled on the massager. The Cradle is placed on a chair or firm surface and the user sits on the massager with the two-bump end forward; this cradles and massages the crotch or perineum area between the testicles and tailbone, as well as the pelvic floor muscle group, lymph glands, and prostate gland.

Prostate stimulation can create pleasurable, tingling sensations which travel up the spine for a feel-good experience; the $39 price tag is also a plus and less than a doctor's visit.

The Prostate Cradle is made from the highest-quality material available. Over the years, many prototypes have been tested to achieve an ideal form of correct universal size, shape, and flexibility, to trigger specific acupressure points, while avoiding others.

Most men are expected to have some type of prostate issue at some point in their lives, if they live long enough. In addition, prostate cancer is a leading form of cancer and has a high casualty rate.

"We need to defend ourselves." McVay said. "That means powering-up our immune systems through nutrition, exercise, and massage; massage can also be used with other forms of therapy, if needed."

Research studies report that prostate massage is effective in reduction, and in some cases, curing prostate issues without drugs or surgery. If caught early enough, additional problems are preventable; it is common to have an enlarged prostate before experiencing symptoms.

Healthy prostates can also benefit from massage as preventative therapy. The Prostate Cradle can act as a "trainer" to discover the entire perineum or male "G-spot" area.

A guide booklet accompanies the Prostate Cradle, and discusses not only how to have better orgasms, but, how to have the "right kind."

Additional benefits of prostate massage include: creating positive energy, burning calories, reducing tension, and eliminating negative emotions like guilt and anger. Prostate massage can also help to release primal, euphoria- inducing chemicals such as adrenaline and endorphins.

The Prostate Cradle works as a natural alternative to prescription therapy by stimulating arousal periods, indefinitely. This can help equal the sensual playing field between partners; if a healthy prostate is massaged correctly, it can become super stimulated and feel like it is glowing.

"Perhaps this is why ancient texts refer to the prostate as the gateway to the universe," McVay said.

To learn more about the Prostate Cradle, visit: www.ProstateCradle.com